A strategic discovery roadmap towards high-quality leads and drug development candidates for kinetoplastid diseases. Part 2: from molecule to confirmed hit
Bron
The journal of antimicrobial chemotherapy - ISSN 0305-7453-81:4 (2026) p. 1-14
Bridging antileishmanial drug discovery and cell biology : from mode of action studies to targeting intracellular trafficking
Bron
Antwerp, University of Antwerp, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, Department of Biomedical Sciences, 2026,213 p.
Structural and functional insights into the Leishmania donovani dynamin-1-like protein as a promising drug target
Bron
Antwerp, University of Antwerp, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, Department of Pharmaceutical Sciences, 2026,XXII, 255 p.
Cytotoxicity and antimicrobial activity of GaMF1 analogs
Bron
ChemMedChem - ISSN 1860-7179-21:4 (2026) p. 1-17
The EamA metabolite transporter does not affect antileishmanial drug susceptibility
Bron
International Journal for Parasitology: Drugs and Drug Resistance - ISSN 2211-3207-30 (2026) p. 1-8